This site has been created solely for the purpose of providing information about services available from Richmond Pharmacology. The site has been compiled in good faith from information available at the time and is therefore subject to change at any time and without notification.
Mission Statement
Our Mission Statement guides our employees, volunteers and stakeholders and outlines our goals and objectives as an organisation.
Five Years Since a World-First CRISPR Breakthrough at Richmond Pharmacology
December 8, 2025
In November 2020, Richmond Pharmacology made medical history when a patient received the first-ever systemically delivered CRISPR therapy, using lipid nanoparticles to edit genes directly inside the human body.
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
